Genmab — Marts 2017
-
Jeg er meget tilfreds. Er enig med Danske som understregerher til morgen, at udrulningen outperformer konkurrenterne. Forløbig er salget for Jan og feb over deres estimater.
-
enig
-
Banken mener også at deres estimat for hele Q1 på 188 mil kan blive overgået.
-
Ja.
-
(tom indlæg)
-
De fastholder estimat på 1.400 i samlet salg i 2017.
-
(tom indlæg)
-
Danske konkluderer,
at februar er en smule bedre end deres forventninger. -
Endvidere "We see upside to the guidance based on:
• Daily sales projections using the growth trend for the past 12 months (6-7%), suggesting USD 1.1bn in US Darzalex sales in 2017 (see calculations below), with the European sales then being added.
• Potential label expansion in third-line to include a Pomalyst combination.
• Potential off-label sales in frontline MM driven by the upcoming frontline data likely for release in H2." -
Rachel opsummerede i går på Investordagen, at der er ialt 40 igangværende forsøg med Dara
. -
Mekanismen bag Daras virkning på immunforsvaret er videnskabeligt klarlagt, men endnu ikke bevist i klinikken.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind